R. Phillpotts, D. Delong, J. Wallace
Jun 20, 1981
Citations
2
Influential Citations
86
Citations
Quality indicators
Journal
The Lancet
Abstract
Abstract In vitro studies have shown the compound 2-amino-1-(isopropyl sulphonyl)-6-benzimidazole phenyl ketone oxime (enviroxime) to be highly active against rhinoviruses. 48 volunteers were given intranasal and oral enviroxime, or placebo, one day before and for five days after infection with rhinovirus type 9. Symptoms of rhinovirus infection and the virus titre of nasal wash specimens were reduced in the enviroxime group, and there was a significant decrease in rhinorrhoea. Although there were some adverse reactions to oral enviroxime, the results indicate that antiviral activity was due to drug administered in the nasal spray and that enviroxime has potential as an antirhinovirus agent for clinical use.